Pamela B. Besada-Lombana

Pamela B. Besada-Lombana

Auto-generated profile, based on publicly available information

Pamela B. Besada-Lombana

Helaina Inc., 345 Park Avenue South, 5th Floor, New York, NY 10010, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2024 in The Analyst
Verified
Journal Article
Closed access
PDF file
XLXiaoning Lu
Xiaoning Lu
CCChad Cummings
Chad Cummings
UOUdodili A. Osuala
Udodili A. Osuala
NYNeela H. Yennawar
Neela H. Yennawar
KNKevin Namitz
Kevin Namitz
ACAnthony J. Clark
Anthony J. Clark
This work presents a thorough characterization of Helaina recombinant human lactoferrin (rhLF, Effera™) expressed in a yeast system at an industrial scale for the first time.

10 May 2024 in Food and Chemical Toxicology
Verified
Journal Article
Open access
RVRoma Vishwanath-Deutsch
Roma Vishwanath-Deutsch
DDDavid Dallas
David Dallas
PBPamela Besada-Lombana
Pamela Besada-Lombana
LKLaura Katz
Laura Katz
DCDietrich B. Conze
Dietrich B. Conze
CMCarrie Malinczak
Carrie Malinczak
Published studies on the glycosylation, absorption, distribution, metabolism, excretion, and safety outcomes of orally ingested recombinant human lactoferrin (rhLF) were reviewed in the context of unanswered safety questions, including alloimmunization, allergenicity, and immunotoxicity potential of rhLF during repeated exposure. The primary objective was to summarize current safety data of rhLF produced in transgenic host expression systems. Overall, results from animal and human studies showed that rhLF was well tolerated and safe. Animal data showed no significant toxicity-related outcomes among any safety or tolerability endpoints. The no observed adverse effect levels (NOAEL) were at the highest level tested in both iron-desaturated and -saturated forms of rhLF. Although one study reported outcomes of rhLF on immune parameters, no animal studies directly assessed immunogenicity or immunotoxicity from a safety perspective. Data from human studies were primarily reported as adverse events (AE). They showed no or fewer rhLF-related AE compared to control and no evidence of toxicity, dose-limiting toxicities, or changes in iron status in various subpopulations. However, no human studies evaluated the immunomodulatory potential of rhLF as a measure of safety. Following this review, a roadmap outlining preclinical and clinical studies with relevant safety endpoints was developed to address the unanswered safety questions.

9 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
XLXiaoning Lu
Xiaoning Lu
CCChad Cummings
Chad Cummings
UOUdodili A. Osuala
Udodili A. Osuala
NYNeela H. Yennawar
Neela H. Yennawar
KNKevin Namitz
Kevin Namitz
ACAnthony J. Clark
Anthony J. Clark
We performed a thorough analysis and characterization of multiple batches of Helaina recombinant human lactoferrin (rhLF, Effera™) expressed at an industrial scale in a yeast system. Bottom-up LC-MS/MS-based proteomics analysis detected the full sequence of Helaina rhLF protein and confirmed that its amino acid sequence is identical to that of native human LF (Uniprot i.d. P02788). Helaina rhLF had a protein purity of 98% or higher as determined by three orthogonal methods; reversed-phase HPLC, SDS-PAGE, and LC-MS proteomics analysis. N-linked glycans were detected at three known glycosylation sites, namely, Asparagines-156, -497, and -642. The identified N-glycans of Helaina rhLF were predominantly oligomannose structures with five to nine mannoses (M5-M9), which we also report to be present in both the native human and bovine LF. human milk LF (hmLF) possessed lower levels of oligomannose structures and were mainly M5 and M6. Helaina rhLF protein secondary structure was nearly identical to that of hmLF, as revealed by microfluidic modulation spectroscopy. Results of small-angle X-ray scattering (SAXS) and analytical ultracentrifugation analyses confirmed that, like hmLF, Helaina rhLF displayed well-folded globular structures in solution. Reconstructed solvent envelopes of Helaina rhLF, obtained through the SAXS analysis, demonstrated a remarkable fit with the reported crystalline structure of iron-bound native hmLF. Differential scanning calorimetry investigations into the thermal stability of Helaina rhLF revealed two distinct denaturation temperatures at 68.7±0.9 °C and 91.9±0.5 °C, consistently mirroring denaturation temperatures observed for apo-and holo-hmLF. Overall, the characterization analysis results affirmed that Helaina rhLF was of high purity and exhibited globular structures closely akin to that of hmLF.